Pulmonary Mycobacterium kansasii disease in immunocompetent host: Treatment outcomes with short‑course chemotherapy.
Indian J Med Microbiol
;
2016 Oct-Dec; 34(4): 516-519
Article
in English
| IMSEAR
| ID: sea-181119
ABSTRACT
Mycobacterium kansasii, most virulent of all atypical mycobacteria, causes pulmonary disease identical to the disease caused by Mycobacterium tuberculosis. Early identification of the species and prompt initiation of treatment for M. kansasii is necessary to prevent morbidity and mortality due to this disease. This case series highlights the similarity in the clinical presentation of both M. tuberculosis and M. kansasii and response to direct observation of short‑course chemotherapy with rifampicin, in the management of pulmonary M. kansasii disease. Larger studies are required to evaluate the long‑term effect of short‑course chemotherapy, especially use of moxifloxacin, in the management of pulmonary M. kansasii disease.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Type of study:
Prognostic study
Language:
English
Journal:
Indian J Med Microbiol
Journal subject:
Microbiology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS